SIRPant Immunotherapeutics

Hummelstown, United States

SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo.

$6.2M raised

Aug 2021

Venture - Series Unknown

Biotechnology Medical Therapeutics

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about SIRPant Immunotherapeutics

How much funding has SIRPant Immunotherapeutics raised?

SIRPant Immunotherapeutics has raised $6.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2021.

Where is SIRPant Immunotherapeutics headquartered?

SIRPant Immunotherapeutics is headquartered in Hummelstown, United States.

What does SIRPant Immunotherapeutics do?

SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo.

What stage is SIRPant Immunotherapeutics at?

SIRPant Immunotherapeutics is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated August 5, 2021.

MLA

"SIRPant Immunotherapeutics — Funding & Investors." VCBacked, August 5, 2021, https://www.vcbacked.co/company/sirpant-immunotherapeutics. Accessed July 3, 2026.

APA

VCBacked. (2021). SIRPant Immunotherapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/sirpant-immunotherapeutics

Wikipedia (cite web)

{{cite web |title=SIRPant Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sirpant-immunotherapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated August 5, 2021.